Bundibugyo virus, a lesser-known relative of Ebola that had caused only two confirmed outbreaks before this year, has infected 7,890 people and killed 3,799 of them in the Democratic Republic of the Congo. The current total is more than eleven times the 695 cases and 138 deaths the World Health Organization had recorded in mid-June, when the outbreak was still young enough that Uganda’s health ministry had logged barely two dozen cases across the border.
The World Health Organization declared the Central African outbreak a public health emergency of international concern on May 17, 2026, and the numbers have kept climbing since. Ituri province, where the first clusters emerged among health care workers, now carries 6,032 of the confirmed cases and 2,764 of the deaths on its own, while North Kivu has absorbed a smaller but still severe share: 1,480 cases and 884 deaths.
Ituri and North Kivu carry the bulk of a fast-moving count
Ituri and North Kivu together account for roughly 95 percent of every confirmed case in the country, according to the European Centre for Disease Prevention and Control’s latest tally of 7,890 cases and 3,799 deaths, and the fatality rate has settled near 48 percent — close to the ratio earlier Bundibugyo outbreaks produced, but applied now to a population many times larger. Nearly 2,000 patients have recovered, and more than 890 remain hospitalized in isolation.
The scale goes beyond geography alone. The outbreak has spread into 63 of the country’s 167 health zones across seven provinces, and the second-largest Ebola outbreak on record is how the Centers for Disease Control and Prevention now classifies it, trailing only the 2014-2016 West Africa epidemic. That marks a sharp acceleration from the 695 cases and 138 deaths the World Health Organization had counted in mid-June, and the CDC notes the outbreak surpassed 1,000 confirmed cases within just 40 days of the response being activated.
A filovirus most people have never had to name
Bundibugyo belongs to the filovirus family that also includes Zaire ebolavirus, the species behind the 2014-2016 epidemic, and it produces the same severe hemorrhagic fever: widespread inflammation, blood vessel damage, uncontrolled bleeding and multi-organ failure. Before this year, the virus had caused only two recognized outbreaks, one in Uganda in 2007 and one in the Democratic Republic of the Congo in 2012, and researchers tracking the current spread say it has already exceeded both of those outbreaks combined.
Nancy Sullivan, a Boston University virologist who studies filovirus biology, points to a slower structural problem sitting underneath the case count: diagnostic capacity in the affected provinces. “Delays in specimen collection, transportation and testing can postpone confirmation by days or weeks, which hinders the isolation of infected persons, contact tracing and outbreak-control measures,” she said. The World Health Organization’s own tracking shows the strain that causes — as of early September, field teams had managed to monitor only 85.3 percent of identified contacts in an outbreak that spreads through direct exposure to bodily fluids.
No licensed vaccine, but four candidates in the pipeline
No vaccine has been approved specifically for Bundibugyo ebolavirus, even though two licensed vaccines already protect against Zaire ebolavirus. The World Health Organization has run an investigational vaccination effort inside the outbreak zone regardless, reaching just over 2,000 people across six health zones as of early September.
Behind that stopgap campaign, four vaccine candidates are moving through parallel development with backing from the Coalition for Epidemic Preparedness Innovations: Moderna’s mRNA-1469, two rVSV-based candidates from IAVI/Hilleman Labs and Public Health Vaccines, and an Oxford-designed ChAdOx candidate manufactured by the Serum Institute of India. Moderna’s shot entered its first human trial on August 3, 2026, testing safety and immune response in roughly 80 healthy adult volunteers across three sites in Canada. CEPI’s chief executive, Richard Hatchett, said every candidate that reaches clinical trials gives the response another chance at a safe, effective vaccine.
Uganda’s linked outbreak closed in August; the Congo’s has not
Uganda’s smaller, linked outbreak told a different story. It logged only 20 cases and two deaths, almost all tied to travelers arriving from the Democratic Republic of the Congo, and the World Health Organization declared it over on August 25, 2026, after 42 days passed without a new confirmed case.
No similar declaration is close for the Democratic Republic of the Congo. Case counts there were still rising through late September, and the fatality rate has held near 48 percent even as the confirmed total climbed past the combined toll of the 2007 and 2012 outbreaks many times over. Sullivan’s diagnostic-delay warning, and four vaccine candidates still in trials rather than in arms, point toward the same conclusion the case numbers already suggest: the virus most people had never heard of before this year is not finished adding to them.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Early electric-car owners are hitting battery and screen failures no one warned them about
- A magnitude 5.3 quake struck off the Oregon coast this week
- Amazon’s Prime refunds are rising to $200 as millions more customers become eligible
- A handful of car engines are so tough mechanics say they almost never wear out
